- Home
- KURA vs GERN Comparison
KURA vs GERN Comparison
Compare KURA & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KURA
- GERN
- Stock Information
- Founded
- KURA 2014
- GERN 1990
- Country
- KURA United States
- GERN United States
- Employees
- KURA N/A
- GERN N/A
- Industry
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- KURA Health Care
- GERN Health Care
- Exchange
- KURA Nasdaq
- GERN Nasdaq
- Market Cap
- KURA 713.5M
- GERN 823.0M
- IPO Year
- KURA N/A
- GERN 1996
- Fundamental
- Price
- KURA $10.27
- GERN $1.26
- Analyst Decision
- KURA Strong Buy
- GERN Buy
- Analyst Count
- KURA 13
- GERN 7
- Target Price
- KURA $25.00
- GERN $3.17
- AVG Volume (30 Days)
- KURA 1.9M
- GERN 7.3M
- Earning Date
- KURA 11-04-2025
- GERN 11-05-2025
- Dividend Yield
- KURA N/A
- GERN N/A
- EPS Growth
- KURA N/A
- GERN N/A
- EPS
- KURA N/A
- GERN N/A
- Revenue
- KURA $83,279,000.00
- GERN $164,447,000.00
- Revenue This Year
- KURA $68.63
- GERN $172.62
- Revenue Next Year
- KURA $141.59
- GERN $56.87
- P/E Ratio
- KURA N/A
- GERN N/A
- Revenue Growth
- KURA N/A
- GERN 11877.20
- 52 Week Low
- KURA $5.41
- GERN $1.09
- 52 Week High
- KURA $19.73
- GERN $4.50
- Technical
- Relative Strength Index (RSI)
- KURA 57.06
- GERN 47.34
- Support Level
- KURA $10.18
- GERN $1.19
- Resistance Level
- KURA $11.06
- GERN $1.31
- Average True Range (ATR)
- KURA 0.62
- GERN 0.05
- MACD
- KURA -0.02
- GERN 0.00
- Stochastic Oscillator
- KURA 60.35
- GERN 58.33
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.